Literature DB >> 21664759

The functional role of reactive stroma in benign prostatic hyperplasia.

Isaiah G Schauer1, David R Rowley.   

Abstract

The human prostate gland is one of the only internal organs that continue to enlarge throughout adulthood. The specific mechanisms that regulate this growth, as well as the pathological changes leading to the phenotype observed in the disease benign prostatic hyperplasia (BPH), are essentially unknown. Recent studies and their associated findings have made clear that many complex alterations occur, involving persistent and chronic inflammation, circulating hormonal level deregulation, and aberrant wound repair processes. BPH has been etiologically characterized as a progressive, albeit discontinuous, hyperplasia of both the glandular epithelial and the stromal cell compartments coordinately yielding an expansion of the prostate gland and clinical symptoms. Interestingly, the inflammatory and repair responses observed in BPH are also key components of general wound repair in post-natal tissues. These responses include altered expression of chemokines, cytokines, matrix remodeling factors, chronic inflammatory processes, altered immune surveillance and recognition, as well as the formation of a prototypical 'reactive' stroma, which is similar to that observed across various fibroplasias and malignancies of a variety of tissue sites. Stromal tissue, both embryonic mesenchyme and adult reactive stroma myofibroblasts, has been shown to exert potent and functional regulatory control over epithelial proliferation and differentiation as well as immunoresponsive modulation. Thus, the functional biology of a reactive stroma, within the context of an adult disease typified by epithelial and stromal aberrant hyperplasia, is critical to understand within the context of prostate disease and beyond. The mechanisms that regulate reactive stroma biology in BPH represent targets of opportunity for new therapeutic approaches that may extend to other tissue contexts. Accordingly, this review seeks to address the dissection of important factors, signaling pathways, genes, and other regulatory components that mediate the interplay between epithelium and stromal responses in BPH.
Copyright © 2011 International Society of Differentiation. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21664759      PMCID: PMC3179838          DOI: 10.1016/j.diff.2011.05.007

Source DB:  PubMed          Journal:  Differentiation        ISSN: 0301-4681            Impact factor:   3.880


  153 in total

Review 1.  Myofibroblasts. I. Paracrine cells important in health and disease.

Authors:  D W Powell; R C Mifflin; J D Valentich; S E Crowe; J I Saada; A B West
Journal:  Am J Physiol       Date:  1999-07

2.  Tenascin-C promotes cell survival by activation of Akt in human chondrosarcoma cell.

Authors:  Jun-Hyeog Jang; Chong-Pyoung Chung
Journal:  Cancer Lett       Date:  2005-01-18       Impact factor: 8.679

3.  Autocrine role of interleukin-8 in induction of endothelial cell proliferation, survival, migration and MMP-2 production and angiogenesis.

Authors:  Aihua Li; Michelle L Varney; Jason Valasek; Maurice Godfrey; Bhavana J Dave; Rakesh K Singh
Journal:  Angiogenesis       Date:  2005       Impact factor: 9.596

4.  Hepsin promotes prostate cancer progression and metastasis.

Authors:  Olga Klezovitch; John Chevillet; Janni Mirosevich; Richard L Roberts; Robert J Matusik; Valeri Vasioukhin
Journal:  Cancer Cell       Date:  2004-08       Impact factor: 31.743

5.  Pulmonary CXCR2 regulates VCAM-1 and antigen-induced recruitment of mast cell progenitors.

Authors:  Jenny Hallgren; Tatiana G Jones; J Pablo Abonia; Wei Xing; Alison Humbles; K Frank Austen; Michael F Gurish
Journal:  Proc Natl Acad Sci U S A       Date:  2007-12-10       Impact factor: 11.205

6.  Glucocorticoids downregulate gene expression of GM-CSF, NAP-1/IL-8, and IL-6, but not of M-CSF in human fibroblasts.

Authors:  A Tobler; R Meier; M Seitz; B Dewald; M Baggiolini; M F Fey
Journal:  Blood       Date:  1992-01-01       Impact factor: 22.113

7.  Prostatic stromal cells derived from benign prostatic hyperplasia specimens possess stem cell like property.

Authors:  Victor K Lin; Shih-Ya Wang; Dolores V Vazquez; Chet C Xu; Sheng Zhang; Liping Tang
Journal:  Prostate       Date:  2007-09-01       Impact factor: 4.104

8.  Activation of Erk1/2 and Akt following unilateral ureteral obstruction.

Authors:  Ana B Rodríguez-Peña; Maria T Grande; Nélida Eleno; Miguel Arévalo; Carmen Guerrero; Eugerio Santos; José M López-Novoa
Journal:  Kidney Int       Date:  2008-04-30       Impact factor: 10.612

9.  Localization of a cryptic binding site for tenascin on fibronectin.

Authors:  Kenneth C Ingham; Shelesa A Brew; Harold P Erickson
Journal:  J Biol Chem       Date:  2004-05-03       Impact factor: 5.157

Review 10.  The senescence-associated secretory phenotype: the dark side of tumor suppression.

Authors:  Jean-Philippe Coppé; Pierre-Yves Desprez; Ana Krtolica; Judith Campisi
Journal:  Annu Rev Pathol       Date:  2010       Impact factor: 23.472

View more
  49 in total

1.  Activity landscape analysis of novel 5α-reductase inhibitors.

Authors:  J Jesús Naveja; Francisco Cortés-Benítez; Eugene Bratoeff; José L Medina-Franco
Journal:  Mol Divers       Date:  2016-02-01       Impact factor: 2.943

2.  Age-related histological and zinc content changes in adult nonhyperplastic prostate glands.

Authors:  Vladimir Zaichick; Sofia Zaichick
Journal:  Age (Dordr)       Date:  2013-07-14

Review 3.  Mesenchymal stem cells and the embryonic reawakening theory of BPH.

Authors:  W Nathaniel Brennen; John T Isaacs
Journal:  Nat Rev Urol       Date:  2018-11       Impact factor: 14.432

4.  Laser-capture Microdissection of Human Prostatic Epithelium for RNA Analysis.

Authors:  Giovanni Lugli; Yachana Kataria; Zachary Richards; Peter Gann; Xiaofeng Zhou; Larisa Nonn
Journal:  J Vis Exp       Date:  2015-11-26       Impact factor: 1.355

Review 5.  The reactive stroma microenvironment and prostate cancer progression.

Authors:  David A Barron; David R Rowley
Journal:  Endocr Relat Cancer       Date:  2012-10-30       Impact factor: 5.678

Review 6.  Targeting phenotypic heterogeneity in benign prostatic hyperplasia.

Authors:  Douglas W Strand; Daniel N Costa; Franto Francis; William A Ricke; Claus G Roehrborn
Journal:  Differentiation       Date:  2017-08-04       Impact factor: 3.880

Review 7.  Personalized medicine for the management of benign prostatic hyperplasia.

Authors:  Seth K Bechis; Alexander G Otsetov; Rongbin Ge; Aria F Olumi
Journal:  J Urol       Date:  2014-02-25       Impact factor: 7.450

8.  Sonic hedgehog signals to multiple prostate stromal stem cells that replenish distinct stromal subtypes during regeneration.

Authors:  Yu-Ching Peng; Charles M Levine; Sarwar Zahid; E Lynette Wilson; Alexandra L Joyner
Journal:  Proc Natl Acad Sci U S A       Date:  2013-11-11       Impact factor: 11.205

9.  The senescence-associated secretory phenotype promotes benign prostatic hyperplasia.

Authors:  Paz Vital; Patricia Castro; Susan Tsang; Michael Ittmann
Journal:  Am J Pathol       Date:  2014-01-13       Impact factor: 4.307

10.  Estrogen receptor β, a regulator of androgen receptor signaling in the mouse ventral prostate.

Authors:  Wan-Fu Wu; Laure Maneix; Jose Insunza; Ivan Nalvarte; Per Antonson; Juha Kere; Nancy Yiu-Lin Yu; Virpi Tohonen; Shintaro Katayama; Elisabet Einarsdottir; Kaarel Krjutskov; Yu-Bing Dai; Bo Huang; Wen Su; Margaret Warner; Jan-Åke Gustafsson
Journal:  Proc Natl Acad Sci U S A       Date:  2017-04-24       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.